Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Curacle Co., Ltd. (365270:KRX), powered by AI.
Curacle Co., Ltd. is currently trading at ₩14,760. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Curacle Co., Ltd. on Alpha Lenz.
Curacle Co., Ltd.'s P/E ratio is -18.0.
“Curacle Co., Ltd. trades at a P/E of -18.0 (undervalued) with modest ROE of -54.0%.”
Ask for details →Curacle Co., Ltd. is a biopharmaceutical company dedicated to the research and development of therapeutic solutions focused primarily on innovative treatments for vascular and metabolic diseases. The company's primary function is to develop clinical-stage biopharmaceutical therapies that address significant unmet medical needs. Curacle operates predominantly within the healthcare and life sciences sector, where its products aim to impact medical technology and treatment options. By leveraging advanced scientific research and clinical trials, Curacle seeks to offer novel solutions for complex health conditions. Within the financial market, Curacle represents a part of the innovative biotech segment, highlighting its role as a player in advancing pharmaceutical development. Curacle's progress and breakthroughs hold implications for healthcare advancements, offering potential improvements in quality of life for patients worldwide.
“Curacle Co., Ltd. trades at a P/E of -18.0 (undervalued) with modest ROE of -54.0%.”
Ask for details →Curacle Co., Ltd. (ticker: 365270) is a company listed on KRX in the Healthcare sector (Biotechnology). Market cap is $325.8B.
The current price is ₩14,760 with a P/E ratio of -17.99x and P/B of 8.78x.
ROE is -54.03% and operating margin is -232394.04%. Annual revenue is $7M.